153,338 Shares in Omnicell, Inc. $OMCL Purchased by Empowered Funds LLC

Key Points

• Empowered Funds LLC acquired 153,338 Omnicell shares in the second quarter, worth approximately $6.4 million and representing about 0.34% of the company. Institutional investors collectively own 97.7% of Omnicell.
• Analyst sentiment remains generally positive, with seven Buy ratings, one Hold and one Sell. Omnicell has a consensus “Moderate Buy” rating and an average price target of $57.86, though some analysts recently lowered their targets.
• Omnicell reported quarterly EPS of $0.94, beating estimates of $0.47, while revenue rose 7.4% year over year to $312.2 million. The stock opened at $33.08, near the lower end of its 52-week range.

Empowered Funds LLC acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 153,338 shares of the company's stock, valued at approximately $6,367,000. Empowered Funds LLC owned approximately 0.34% of Omnicell as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Dana Investment Advisors Inc. purchased a new stake in Omnicell in the fourth quarter worth $3,445,000. Bank of America Corp DE grew its position in shares of Omnicell by 31.3% in the 1st quarter. Bank of America Corp DE now owns 580,875 shares of the company's stock worth $19,390,000 after buying an additional 138,537 shares during the period. Jackson Creek Investment Advisors LLC bought a new position in shares of Omnicell in the 4th quarter worth about $2,022,000. Dimensional Fund Advisors LP increased its stake in shares of Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company's stock worth $81,791,000 after acquiring an additional 137,834 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in Omnicell by 2.0% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company's stock valued at $47,095,000 after acquiring an additional 27,497 shares during the period. Institutional investors own 97.70% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. KeyCorp reaffirmed an "overweight" rating on shares of Omnicell in a research note on Monday, August 24th. Piper Sandler reissued an "overweight" rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Zacks Research downgraded Omnicell from a "hold" rating to a "strong sell" rating in a research note on Friday, August 7th. Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 10th. Finally, Wells Fargo & Company dropped their target price on Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Omnicell currently has an average rating of "Moderate Buy" and a consensus target price of $57.86.

Omnicell Price Performance

NASDAQ:OMCL opened at $33.08 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The firm has a market cap of $1.50 billion, a P/E ratio of 39.38, a P/E/G ratio of 0.83 and a beta of 0.98. Omnicell, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The firm has a 50-day simple moving average of $39.80 and a two-hundred day simple moving average of $39.35.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. During the same quarter in the prior year, the firm posted $0.45 earnings per share. The business's revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Analysts predict that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source